EyeGate Pharmaceuticals, Inc. / Fundamentals
Income statement
- Net revenue
€13.81M - Cost of goods sold
€0.00 - Gross profit
-€17.26K - SG&A expenses
€4.75M - R&D expenses
€9.00M - EBITDA
€5.09M - D&A
-€9.54K - EBIT
€677.84K - Interest expenses
-€18.51K - EBT
€5.62M - Tax expenses
-€1.79M - Net income
€7.39M
Cash flow statement
- Net deferred tax
-€249.20K - Non-cash items
€7.78M - Changes in working capital
-€5.56M - Operating cash flow
€6.01M - Capex
€28.23K - Other investing cash flow
€0.00 - Net investing cash flow
-€16.67M - Total cash dividends paid
€0.00 - Issuance of common stock
€0.00 - Debt repayment
€0.00 - Other financing cash flow
-€7.95M - Net financing cash flow
€5.42M - Foreign exchange effects
€132.03K - Net change in cash
-€4.78M - Cash at end of period
€891.33K - Free cash flow
€6.03M
Balance sheet
- Cash and cash equivalents
€887.48K - Cash and short-term investments
€17.84M - Total receivables
€0.00 - Inventory
€0.00 - Other current assets
€3.51M - Total current assets
€21.35M - Property, plant & equipment
€393.42K - Goodwill
€0.00 - Intangible assets
€5.77M - Long-term investments
€0.00 - Other non-current assets
€56.50K - Total non-current assets
€6.22M - Total assets
€27.57M - Accounts payable
€243.84K - Short-term debt
€123.70K - Other current liabilities
€1.30M - Total current liabilities
€2.75M - Long-term debt
€247.76K - Deferred tax liabilities
€423.48K - Other non-current liabilities
€5.05M - Total non-current liabilities
€5.72M - Total liabilities
€8.47M - Common stock
€234.75K - Retained earnings
-€127.49M - Other equity
-€212.11K - Total equity
€19.10M - Total liabilities and shareholders' equity
€27.57M
Company information
- Market capitalization
€22.79M - Employees
14 - Enterprise Value
€22.88M
Company ratios
- Gross margin
-
-0.1% Worse than peer group: 15.7% - EBITDA margin
-
36.9% Much better than peer group: -24,454.4% - EBIT margin
-
4.9% Much better than peer group: -17,146.1% - EBT margin
-
40.7% Much better than peer group: -27,093.5% - Net margin
-
53.5% Much better than peer group: -25,888.5% - ROE
-
38.7% Much better than peer group: -484.4% - ROA
-
26.8% Much better than peer group: -488.4% - Asset turnover
-
50.1% Much better than peer group: 9.8% - FCF margin
-
43.3% Much better than peer group: -6,987.3% - FCF yield
26.2% - Efficiency ratio
63.1% - Net sales per employee
-
€986.33K - Net income per employee
-
€528.16K